Plasma Phosphorylated Tau 217 and Amyloid Burden in Older Adults Without Cognitive Impairment
These findings demonstrate that plasma p-tau217 can reliably detect AD pathology in the preclinical stage. These findings support the clinical utility of plasma p-tau217 as a scalable, minimally invasive tool for early identification of AD, particularly in settings where timely intervention with disease-modifying therapies may offer the greatest benefit in slowing or preventing disease progression.
Authors
- Fawaz Stipho
- Nicholas James Ashton (ORCID: https://orcid.org/0000-0002-3579-8804)
- Michael Denkinger (ORCID: https://orcid.org/0000-0002-8097-060X)
- Wagner S. Brum (ORCID: https://orcid.org/0000-0002-9777-0559)
- Michael Malek‐Ahmadi (ORCID: https://orcid.org/0000-0001-9901-3650)
- Shilpa Sharma (ORCID: https://orcid.org/0009-0006-5019-4722)
- Alpana Singh
Institutions
- Alzheimer's Association (US)
- Universidade Federal do Rio Grande do Sul (BR)
- University of Arizona (US)
- University of Phoenix (US)
- Maricopa Community Colleges - Glendale Community College (US)
- Banner Sun Health Research Institute (US)
- Banner Alzheimer’s Institute
- Phoenix College (US)
- University of Gothenburg (SE)
Publication Details
- Journal
- JAMA Neurology
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1001/jamaneurol.2025.4721
- Citations
- 1
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.16